Education
About Us
Working with TipRanks
Follow Us
Renovaro Biosciences (RENB)
NASDAQ:RENB
RENB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.26 - $2.10
Previous CloseN/A
Volume455.11K
Average Volume (3M)2.93M
Market Cap
$75.19M
Enterprise Value$64.46M
Total Cash (Recent Filing)$923.00K
Total Debt (Recent Filing)$7.03M
Price to Earnings (P/E)―
Beta1.68
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding230,928,970
10 Day Avg. Volume1,331,902
30 Day Avg. Volume2,927,504
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.62
Price to Sales (P/S)0.00
P/FCF Ratio<0.01
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue88.81
Enterprise Value/Gross Profit710.45
Enterprise Value/Ebitda-0.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Renovaro Biosciences News
PremiumCompany Announcements
Renovaro Biosciences Chairman Announces Resignation
PremiumCompany Announcements
Renovaro Biosciences Receives Nasdaq Compliance Notice
PremiumCompany Announcements
Renovaro Biosciences Restructures Debt with Exchange AgreementPremiumCompany Announcements
Renovaro Biosciences Subsidiary CEO Resigns AbruptlyOptions Prices
Currently, No data available
---
Ownership Overview
24.50% Insiders
4.88% Mutual Funds
0.05% Other Institutional Investors
67.65% Public Companies and
Individual Investors
RENB FAQ
What was Renovaro Biosciences’s price range in the past 12 months?
Renovaro Biosciences lowest stock price was $0.26 and its highest was $2.10 in the past 12 months.
What is Renovaro Biosciences’s market cap?
Renovaro Biosciences’s market cap is $75.19M.
When is Renovaro Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Renovaro Biosciences’s earnings last quarter?
Currently, no data Available
Is Renovaro Biosciences overvalued?
According to Wall Street analysts Renovaro Biosciences’s price is currently Overvalued.
Does Renovaro Biosciences pay dividends?
Renovaro Biosciences does not currently pay dividends.
What is Renovaro Biosciences’s EPS estimate?
Renovaro Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renovaro Biosciences have?
Renovaro Biosciences has 230,928,970 shares outstanding.
What happened to Renovaro Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Renovaro Biosciences?
Currently, no hedge funds are holding shares in RENB
Renovaro Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.00%
12-Months-Change
Fundamentals
Return on Equity
-67.13%
Trailing 12-Months
Asset Growth
-33.89%
Trailing 12-Months
Company Description
Renovaro Biosciences
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.